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Abstract The toxicological detection of the new syn-
thetic cathinone 40-methyl-a-pyrrolidinohexanophenone
(MPHP) in urine samples has been impossible, because
much of MPHP is metabolized before its excretion into
urine. In this study, we successfully quantified unmetabo-
lized MPHP in urine of an autopsy case using a sensitive
method by liquid chromatography–time-of-flight-mass
spectrometry. The quantification method showed good
linearity in the range of 1.00–100 ng/mL, and the limit of
detection was 0.5 ng/mL in human urine. In the autopsy
case, the concentrations of MPHP in urine, plasma, and liver
tissue samples were determined to be 60.1, 32.9 ng/mL, and
63.1 ng/g, respectively.
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Introduction
The new designer drug 40-methyl-a-pyrrolidinohex-
anophenone (MPHP) is a synthetic cathinone classified as
an a-pyrrolidionophenone derivative (see reviews [1, 2]).
MPHP was first identified in seized products as a drug of
abuse in Germany in 2000 [3]. In Japan, MPHP has been
detected in many types of seized products including mixed
dried plants called ‘‘herbs,’’ powder-type products called
‘‘bath salts,’’ and liquid-type products called ‘‘liquid
aroma’’ because it was first identified in distributed illegal
products in 2013 [4].
MPHP is presumed to exhibit stimulant effects and
serious toxicity like other synthetic cathinones and
amphetamines [2, 5, 6]. There is only one report on acute
poisoning with toxic liver damage and rhabdomyolysis
after MPHP intake [7]. In this poisoning case, MPHP was
found at a concentration of 100 ng/mL in the patient’s
serum by gas chromatography–mass spectrometry (GC–
MS), while it could not be detected in urine because of its
metabolism [7], which is consistent with the findings in a
study on MPHP metabolites in rat urine [8]. MPHP could
not be found in rat urine 24 h after administration with
either 1 mg/kg, which corresponds to the common dose of
abusers, or 20 mg/kg by GC–MS with a limit of detection
of 100 ng/mL [8]. Conversely, the main urinary MPHP
metabolite 40-carboxy-a-pyrrolidinohexanophenone (40-
carboxy-PHP) could be detected in both human [7] and rat
[8] urine after MPHP administration. Therefore, to date, the
toxicological detection of MPHP in urine by GC–MS
seems to be possible only via its metabolites, including 40-
carboxy-PHP, but these compounds are not commercially
available [9]. Recently, Minakata et al. [10] reported that a
matrix-assisted laser desorption ionization-quadrupole
time-of-flight-mass spectrometry enabled the sensitive
quantification of MPHP with a range of 2–100 ng/mL,
although the samples used consisted of blood from vol-
unteers with MPHP added as a reference. In the present
study, we are the first to identify and quantify MPHP in
human postmortem urine by using liquid chromatography–




1 Department of Forensic Medicine, Graduate School of
Medical Science, Kyoto Prefectural University of Medicine,
465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
123
Forensic Toxicol (2016) 34:398–402
DOI 10.1007/s11419-016-0307-z
Case history
A 52-year-old man started to thrash about suddenly
while sleeping and had a general convulsion. His wife
and two children held down his arms and legs for
approximately 20 min until his convulsion calmed down.
At this point, his family assumed that the patient had
fallen asleep again. They suspected abuse of designer
drugs as a cause of his convulsion because he had been
suspected of possession of illegal designer drugs and was
questioned by the police 4 months earlier. The family
then searched the living room for drugs and found eight
packages consisting of one black package labeled
‘‘Zombie,’’ three clear packages ‘‘Bolt 1G,’’ ‘‘Aladdin
pre 1G,’’ and ‘‘Spica 0.2’’ written on them, and four
unlabeled clear packages. His wife returned to the bed-
room and found him dead. An autopsy was performed at
our department 1.5 days later. He had no notable medi-
cal history, but his daughter had seen him thrashing
about approximately 1 month earlier.
Alcohol was not detected in either blood or urine sam-
ples by GC. Testing of urine samples by a Triage DOA kit
(Sysmex, Kobe, Japan) showed negative results. Screening
of a forensic toxicology library (MassLynx 4.1 TOF Tox-
icology Database 1; Waters, Milford, MA, USA) using a
LC–TOF-MS system (ACQUITY UPLC-Xevo G2-S





(MeOPPP) were purchased from Cayman Chemical Co.
(Ann Arbor, MI, USA). Other common chemicals were of
analytical grade and purchased from Wako Pure Chemical
Industries Ltd. (Osaka, Japan).
Blank blood and urine samples were collected from
healthy volunteers with no history of drug intake after
informed consent was obtained. The blank samples were
screened for common drugs of abuse, alcohol, and MPHP
and all were confirmed to be negative.
Sampling and sample preparation
Heart blood, urine, and liver tissue samples were collected
at autopsy. The blood samples were centrifuged at
16009g for 10 min immediately after autopsy to prepare
plasma. The plasma, urine and liver tissue samples were
stored at -20 C until use.
Liver tissue specimens were homogenized with 4 times
(v/w) the amount of ultra-pure water using a bead beater-
type shaking machine (TissueLyser II; QIAGEN, Hilden,
Germany), and then the homogenate was diluted two-fold
with ultra-pure water. Forty-five microliter samples of
plasma, urine, or diluted liver tissue homogenate were
deproteinized with 100 lL of acetone, and followed by the
addition of 5 ll of 1.0 lg/mL MeOPPP as an internal
standard. After centrifugation at 10,0009g for 5 min, the
supernatant was used for LC–TOF-MS analyses.
LC–TOF-MS conditions
LC–TOF-MS conditions were exactly the same as descri-
bed in our previous report [11]. Briefly, LC–TOF-MS was
conducted on a Waters ACQUITY UPLC system with a
quadrupole time-of-flight MS system (Xevo G2-S QTof;
Waters). LC separation was performed with a Waters
ACQUITY UPLC HSS C18 column (2.1 9 150 mm,
1.8 mm i.d., 1.8 lm particle size) with an aqueous solution
of 5 mM ammonium formate adjusted to pH 3.0 using
formic acid (solvent A) and an acetonitrile solution con-
taining 0.1 % (v/v) formic acid (solvent B) for the mobile
phases. The gradient elution mode was employed using the
solvents A and B as described [11].
Results and discussion
Prediction of the main compound present
in the urine samples by LC–TOF-MS
Figure 1a, b shows the total ion current chromatogram
(TIC) of LC–TOF-MS obtained from the deceased’s urine
sample, and the mass spectrum of the main TIC peak at a
retention time of 3.63 min, respectively. Elemental com-
position analysis with the exact mass of the protonated
precursor monoisotopic ion (290.1775) acquired with a
collision energy of 6 eV predicted the formula C17H24NO3
(calculated 290.1756). These results suggested the main
metabolite of MPHP, that is, 40-carboxy-PHP [8, 12, 13],
because MPHP is the main component of ‘‘Zombie’’ and
‘‘Aladdin’’ [14], which were found in the deceased’s living
room. The fragment patterns of the target ion acquired
using collision energy ramp of 10-40 eV (Fig. 1c) indi-
cated 40-carboxy-PHP by molecular structure analyses
(Mass Fragment software; Waters) (Fig. 1d, Table 1).
Identification of MPHP in the urine sample
To examine whether the parent compound MPHP was
present in the urine sample, target ions at m/z
260.202 ± 0.010, which were determined by analysis with
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the purchased reference standard of MPHP (right panel in
Fig. 2b), were extracted (left panel in Fig. 2a). The reten-
tion time of the extracted ion chromatogram (XIC)
(7.05 min in Fig. 2a), the exact mass of the protonated
precursor ion (260.2007) acquired using a collision energy
of 6 eV (Fig. 2b), and the full-spectrum of the fragment
ions acquired with a collision energy ramp of 10–40 eV
(Fig. 2c) in the urine sample (left panel in each figure)
coincided with those of the reference standard (right panels
in Fig. 2). These results demonstrated the identification of
the parent compound MPHP in the deceased’s urine.
Similarly, MPHP was also identified in the plasma and
liver tissue samples (data not shown).
Quantification of MPHP in urine, plasma, and liver
tissue samples
The quantification of MPHP was conducted for the three
samples taken from the deceased. Linear calibration was
achieved in the range 1.00–100 ng/mL for urine
(y = 0.0210x ? 0.000480; r = 0.9991). The limit of detec-
tion (signal-to-noise ratio C 3) for MPHP in urine was
0.5 ng/mL. The limit of quantification was defined as the
lowest point of the calibration curve (1.0 ng/mL). Recoveries
at two different concentrations together with intraday preci-
sion and accuracy in the urine samples are shown in Table 2.
All parameters were within the acceptable range. The
regression equation, limit of detection, and limit of quantifi-
cation for plasmawere y = 0.0202x ? 0.00328 (r =0.9966),
1.0 ng/mL, and 1.0 ng/mL, respectively. For quantification
with the liver tissue samples, the standard addition method
[15] was adopted considering the greater matrix effects in the
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Fig. 1 Total ion current
chromatogram (a), mass spectra
of the precursor ion (b), and
fragment ions (c) of a peak with
a retention time of 3.63 min




MS). d shows the disconnection
sites of 40-carboxy-a-
pyrrolidinohexanophenone
predicted in molecular structure
analysis for the full-spectrum of
the fragment ions (c)
Table 1 Molecular structure analyses with the fragment pattern of a
target ion obtained from the deceased’s urine sample




a An index of the energy required for disconnecting the bond
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liver sample than in plasma and urine samples. The regression
equation in liver tissue homogenate was y = 0.00198x ?
0.125 (r = 0.9996). The concentrations ofMPHP in the urine,
plasma, and liver samples were 60.1 ng/mL, 32.9 ng/mL and
63.1 ng/g, respectively (Table 3).
Distribution of the MPHP metabolite 40-carboxy-
PHP in the urine, plasma, and liver
To clarify the distribution of 40-carboxy-PHP in the urine,
plasma, and liver, the relative amount of 40-carboxy-PHP
to MPHP in each sample was determined using the ratio
of the peak area on XIC at m/z 290.178 for 40-carboxy-
PHP against the peak area at m/z 260.202 for MPHP
because 40-carboxy-PHP is not commercially available.
The relative amount of 40-carboxy-PHP in plasma and
liver was similar, while that in urine was 28 times more
than in plasma (Table 3). Although it was unclear when
the deceased took MPHP, these results demonstrated that
the majority of MPHP was excreted as its metabolites in













































Fig. 2 Extracted ion/total ion
current chromatogram (a), mass
spectra of the precursor ion
(b) and fragment ions (c) of a
peak with a retention time of
7.05 min obtained from the
deceased’s urine (left panels)
and 40-methyl-a-
pyrrolidinohexanophenone
reference standard together with
an internal standard 40-methoxy-
a-pyrrolidinopropiophenone
(MeOPPP) (right panels) by
LC–TOF-MS. XIC extracted ion
chromatogram at m/z
260.202 ± 0.010; TIC total ion
current chromatograms; asterisk
peak of the internal standard
MeOPPP
Table 2 Intraday recovery, precision, and accuracy data for deter-










1.0 95.6 9.9 -8.5
100 104 5.9 -5.8
RSD relative standard deviation, RE relative error
Table 3 Concentrations of MPHP and relative amounts of 40-car-
boxy-a-pyrrolidinohexanophenone (40-carboxy-PHP) in the urine,
plasma, and liver samples of the deceased
Urine Plasma Liver
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Conclusions
We reported the first successful quantification of MPHP in
an autopsy urine sample using LC–TOF-MS. Although the
majority of MPHP was excreted as the MPHP metabolite
40-carboxy-PHP in urine, the sensitive method of LC–TOF-
MS with a limit of quantification of 1.0 ng/ml was able to
quantify the remaining unmetabolized urinary MPHP.
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